167 related articles for article (PubMed ID: 38656229)
1. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A; Palumbo C; Zamboni S; Mazziotti G; Triggiani L; Zamparini M; Maffezzoni F; Rinaudo L; Bergamini M; Di Meo N; Caramella I; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Berruti A
J Endocrinol Invest; 2024 Feb; 47(2):335-343. PubMed ID: 37458931
[TBL] [Abstract][Full Text] [Related]
3. Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.
Palumbo C; Antonelli A; Triggiani L; Dalla Volta A; Maffezzoni F; Zamboni S; Borghetti P; Rinaudo L; Valcamonico F; Maroldi R; Magrini SM; Simeone C; Berruti A;
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):852-859. PubMed ID: 33723362
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
5. Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Palumbo C; Dalla Volta A; Zamboni S; Mazziotti G; Zamparini M; Triggiani L; Borghetti P; Maffezzoni F; Bresciani R; Rinaudo L; Valcamonico F; Farina D; Magrini SM; Antonelli A; Simeone C; Berruti A
J Clin Endocrinol Metab; 2022 Nov; 107(12):3398-3407. PubMed ID: 35971857
[TBL] [Abstract][Full Text] [Related]
6. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract][Full Text] [Related]
7. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
10. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
11. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
12. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
13. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Langley RE; Kynaston HG; Alhasso AA; Duong T; Paez EM; Jovic G; Scrase CD; Robertson A; Cafferty F; Welland A; Carpenter R; Honeyfield L; Abel RL; Stone M; Parmar MK; Abel PD
Eur Urol; 2016 Jun; 69(6):1016-25. PubMed ID: 26707868
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.
Wang W; Yuasa T; Tsuchiya N; Maita S; Kumazawa T; Inoue T; Saito M; Ma Z; Obara T; Tsuruta H; Satoh S; Habuchi T
Endocr Relat Cancer; 2008 Dec; 15(4):943-52. PubMed ID: 18667685
[TBL] [Abstract][Full Text] [Related]
16. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
17. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
18. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
19. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
[TBL] [Abstract][Full Text] [Related]
20. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
